2023

1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

   Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

2. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

   Therapeutic Advances in Medical Oncology, Vol. 15